Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lilly gains Prozac indications

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Lilly's Prozac (fluoxetine) gains additional indications July 29 for panic disorder, with and without agoraphobia, and longer-term treatment of bulimia. Labeling adds 52-week follow-up data to existing 16-week studies in bulimia; the panic studies were 12 weeks long. Lilly had expected Prozac exclusivity to run until June 2004, but a court decision in August 2001 invalidated its longest-running patents, allowing generics to come to marke
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS002025

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel